EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PROTAC and Molecular Glue Degraders of the Oncogenic RNA Binding Protein Lin28

Aseel Kashkush, Judith Furth-Lavi, Jiri Hodon, Raphael I Benhamou iD

Macromolecular Bioscience · 2025-03 · 25 (3)

DOI: 10.1002/mabi.202400427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Macromolecular Bioscience, online erschienen am 22.11.2024. Verfasst von Aseel Kashkush und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Institute for Drug Research of the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Hadassah-Ein Kerem, Jerusalem, 91…. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Proteolysis, MicroRNAs, Small Molecule Libraries. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Israel Cancer Research Fund (ICRF), Israel Ministry of Innovation, Science and Technology, Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interaction between proteins and RNA is crucial for regulating gene expression, with dysregulation often linked to diseases such as cancer. The RNA‐binding protein (RBP) Lin28 inhibits the tumor suppressor microRNA (miRNA) let‐7, making it a significant oncogenic factor in tumor progression and metastasis. In this study, a small molecule is used that binds Lin28 and blocks its inhibition of let‐7. To enhance its efficay, the inhibitor is transformed into degraders via two degradation approaches: Proteolysis Targeting Chimera (PROTAC) and molecular glue. A series of PROTAC bifunctional molecules and molecular glues capable of degrading Lin28 in cells.is developed Both strategies significantly reduce overexpressed Lin28 and alleviate cancer cellular phenotypes. Notably, the molecular glue approach demonstrates exceptional potency, surpassing PROTAC in several aspects. This outcome underscores the superior efficiency of the molecular glue approach for targeted Lin28 degradation and highlights its potential for addressing associated diseases with small molecules. Innovative small molecule strategies such as molecular glue and PROTAC technology for targeted RBP degradation, hold promise for opening new avenues in RNA modulation and addressing related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsProteolysisMicroRNAsSmall Molecule LibrariesHumansCell Line, Tumor

Stichwörter der Autor:innen

PROTACRNA binding protein (RBP)microRNAmolecular gluetargeted degradation

Substanzen

RNA-Binding ProteinsLin28A protein, humanMicroRNAsmirnlet7 microRNA, humanSmall Molecule Libraries

Autor:innen und Institutionen

  • The Institute for Drug Research of the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Hadassah-Ein Kerem, Jerusalem, 91120, Israel.

ORCID-Profile: Raphael I Benhamou

Förderung

  • Israel Cancer Research Fund (ICRF)
  • Israel Ministry of Innovation, Science and Technology
  • Israel Science Foundation
  • program EXCELES

Zitieren

APA

Kashkush, A., Furth-Lavi, J., Hodon, J., & Benhamou, R. I. (2025). PROTAC and Molecular Glue Degraders of the Oncogenic RNA Binding Protein Lin28. Macromolecular Bioscience, 25(3). https://doi.org/10.1002/mabi.202400427

Vancouver

Kashkush A, Furth-Lavi J, Hodon J, Benhamou RI. PROTAC and Molecular Glue Degraders of the Oncogenic RNA Binding Protein Lin28. Macromolecular Bioscience. 2025;25(3). doi:10.1002/mabi.202400427

BibTeX
@article{Kashkush2025,
  author = {Kashkush, Aseel and Furth-Lavi, Judith and Hodon, Jiri and Benhamou, Raphael I},
  title = {PROTAC and Molecular Glue Degraders of the Oncogenic RNA Binding Protein Lin28},
  journal = {Macromolecular Bioscience},
  year = {2025},
  volume = {25},
  number = {3},
  doi = {10.1002/mabi.202400427}
}
Kostenlos starten →